We show that TCEA3 sensitizes RMS cell lines to chemotherapeutic drugs, suggesting that reactivating TCEA3 in cancer cells is an attractive novel therapeutic target for RMS treatment that would specifically initiate apoptosis in cancer cells while sparing normal cells. The gene discussed is TCEA3; the disease is cancer.